As regulatory pressure accelerates and the phase down of high global warming potential inhaler medical propellants moves from policy to execution, pharmaceutical companies and investors are looking closely at which solutions are safe, sustainable and truly ready to scale. For Orbia Fluor & Energy Materials, Zephex® 152a represents a critical next step in the future of inhaled medicines — and 2026 marks an important year in that journey.
Following the recent approval of Orbia’s Drug Master File in the U.S. and the ramp up of its dedicated, commercial-scale manufacturing plant in the U.K., momentum around Zephex® 152a continues to build. In this Megatrendsetters Q&A, Orbia Fluor & Energy Materials experts Sheryl Johnson and Chris Dodd detail how the transition to Zephex® 152a is unfolding globally.
